Canton Strategic Holdings Inc
cantonstrategic.comWhat Do They Do?
Manages Canton Coin holdings and operates validator services for the Canton Network, supporting institutional blockchain adoption; develops therapeutic candidates in immunology and inflammation.
10-K for FY2025, filed Mar 31, 2026We are the first publicly traded company to leverage Canton Coin (“CC”) and support the Canton Network to advance institutional blockchain…View ↗
Validator Operations and Network Participation: We operate as a Super Validator and intend to run additional validator nodes on the Canton…View ↗
Through our subsidiary Gravitas, we develop therapeutic candidates in immunology and inflammation with high unmet need.View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Super Validators and Featured Applications use its locking service, which locks the company’s CC on a customer’s behalf; its validator and liveness work supports Canton Network activity.
8-K, filed Aug 14, 2026
How Are They Changing?
-
Aug 14, 2026
Sold its legacy biotech subsidiary Gravitas
The sale brought a $3,500,000 note bearing 15% payment-in-kind interest, plus contingent development milestone payments.
Sources
8-K, filed Aug 14, 2026
Streamlined its operations through the sale of Gravitas Life Sciences, Inc. (“Gravitas”), the Company’s legacy clinical-stage biotechnology…View ↗
Strategic focus
The older report centers on oncology drug candidates and tumor-targeting platforms; the latest prioritizes a Canton Coin treasury and participation in the Canton Network, while retaining biotech research and development.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 31, 2026From 2022 through late-2025, we primarily operated as a biotechnology company, developing therapeutic candidates in inflammatory and…View ↗
We believe that the configurable privacy enabled by the Canton Network’s blockchain technology is transforming the future of global finance…View ↗
Through our subsidiary Gravitas, we develop therapeutic candidates in immunology and inflammation with high unmet need.View ↗
Therapeutic focus
The older report describes candidates aimed at treatment-resistant cancers, while the latest describes Gravitas programs in immunology and inflammation, including a buccal nalmefene film and oral infliximab.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 31, 2026Hillstream BioPharma is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new…View ↗
Through our subsidiary Gravitas, we develop therapeutic candidates in immunology and inflammation with high unmet need.View ↗
GV104 (formerly TH104) is a proprietary buccal film formulation of nalmefene, a long-acting opioid antagonist, being developed for…View ↗
GV023 (formerly TH023), is an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. On September 11, 2024, we…View ↗
Loading...
